deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00274989

Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia

Multicentre Phase II Trial of Bendamustine in Combination With Rituximab for Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia. CLL2M Protocol of the German CLL-Study Group (GCLLSG)

Sponsor: German CLL Study Group

Conditions Chronic Lymphocytic Leukemia
Interventions Bendamustine Rituximab
Updated 7 times since 2017 Last updated: May 21, 2019 Started: Nov 30, 2005 Primary completion: Mar 31, 2008 Completion: Mar 31, 2011
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Lymphocytic Leukemia and is currently completed. German CLL Study Group leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshotCompleted~Jun 2019 – ~Jan 2021 · 19 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 11 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2019 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Jun 2018 — Jun 2019 [monthly]

    Completed PHASE2

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • German CLL Study Group
  • University of Cologne
Data source: German CLL Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arnstadt, Germany , Augsburg, Germany , Bad Saarow, Germany , Berlin, Germany , Bochum, Germany , Bottrop, Germany , Bremen, Germany , Cologne, Germany , Darmstadt, Germany , Düsseldorf, Germany and 41 more locations